Anthera Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products to treat serious diseases associated with autoimmune disorders, including lupus, glomerulonephritis and IgA nephropathy. The Company�s primary product candidate, blisibimod, targets elevated levels of B-cell activating factor (BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus, or lupus, IgA nephropathy, lupus nephritis, vasculitis, rheumatoid arthritis, idiopathic thrombocytopenia purpura, and others. It is advancing its development of blisibimod, an inhibitor of BAFF, to expand its potential clinical utility in autoimmune diseases. Blisibimod is a protein compromised of high-affinity BAFF binding domains fused to a human Fc domain, called a peptibody and is distinct from an antibody. It owns worldwide rights to blisibimod in all potential indications.